Article Sidebar

PDF
Date Published: 19/07/2023
Online Published: 19/07/2023
Abstract Views: 3740
Views PDF: 2696
DOI: https://doi.org/10.60137/tmhvn.v68i60.27
Issue
Vol. 68 No. 60
Section
Articles
How to Cite
Nguyen, T. T., Nguyen, T. D., Nguyen, T. N. D., & Tran, P. C. T. (2023). DIAGNOSIS OF GERD BY NON-INVASIVE TEST. Vietnam Journal of Otorhinolaryngology - Head and Neck Surgery, 68(60), 37-46. https://doi.org/10.60137/tmhvn.v68i60.27

DIAGNOSIS OF GERD BY NON-INVASIVE TEST

Thanh Tuan Nguyen , Truc Dung Nguyen, Thi Ngoc Dung Nguyen, Phan Chung Thuy Tran

Main Article Content

Abstract

ackground & Objective: Adductor spasmodic dysphonia (AdSD) is idiopathic focal dystonia characterized by irregular contractions or postural disorders of the laryngeal muscles, resulting in abnormal speech. Currently, the injection ofbotulinum toxin into the thyroarytenoid muscle is highly recommended as the primary treatment modality.
Materials and Methods: This is a prospectively observational study with 40 AdSD patients at the University Medical Center of HCMC between 01/2018 and 01/2022. We usedEMG and endoscopic guidance for BTX injection in adductor spasmodic dysphonia. Evaluation of the results was based on the VHI scores, acoustic analysis, laryngoscopy and perceptual measures.
Results: 40 patients with AdSD were injected with BTX in 96 treatment sessions. The voice handicap index (VHI) levels of the patients were: severe (72.9%), moderate (27.1%) and mild (none). The average VHI score was 74.6 points. After 2 months of BTX treatment, the VHI level was: Severe (8.3%), moderate (106.7%), and mild (75.0%). The average VHI score was 31.4 points. The average values of jitter, shimmer and harmonic to noise ratio (HNR) improved statistically (p < 0.05). The incidence of side effects were: breathiness (17.7%), choking (15.6%); hoarseness (9.4%), and dysphagia (4.2%).
Conclusions: Injection of BTX under both EMG and laryngoscopy guidance for treatment of adductor spasmodic dysphonia is an effective and safe treatment.

Article Details

Keywords

dductor spasmodic dysphonia, botulinum toxin

References

1. Blitzer A. Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series. European Journal of Neurology 2010; 17: 28-30.
2. Schweinfurth JM, Billante M, Courey MS. Risk factors and demographics in patients with spasmodic dysphonia. The Laryngoscope 2002; 112(2): 220-3.
3. Blitzer A, Brin MF, Fahn s, Lovelace RE. Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). The Laryngoscope 1988; 98(2): 193-7.
4. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): A 12-year experience in more than 900 patients. The Laryngoscope 2015; 125(8): 1751-7.
5. whurr R, Lorch M. Review of differential diagnosis and management of spasmodic dysphonia. Current opinion in otolaryngology & head and neck surgery 2016; 24(3): 203-7.
6. Murano E. Botulinum toxin injection for spasmodic dysphonia in Japan. Program and Abstracts of the 5A International Conference 1999: Basic and Therapeutic Aspect of Botulinum and Tetanus Toxins (Orlando, Florida, Nov 15-18, 1999); 1999; 1999.
7. Truong D, Bhidayasiri R. Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes: comparing different botulinum toxin preparations. European Journal of Neurology 2006; 13: 36-41.
8. Huynh QT. Xây dựng VHI (voice handicap index) phiên bản tiếng Việt. Tạp Chí Y Học Tp Hồ Chí Minh 2008; 12(1): 5.
9. Morzaria s, Damrose EJ. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dys- phonia. Journal of Voice 2012; 26(3): 378-80.
10. Elmiyeh B, Prasad VM, Upile T, et al.
A single-centre retrospective review of unilateral and bilateral Dysport® injections in adductor spasmodic dysphonia. Logopedics Phoniatrics Vocology 2010; 35(1): 39-44.
11. Zwirner p, Murry T, Swenson M, Woodson GE. Acoustic changes in spasmodic dysphonia after bot- ulinum toxin injection. Journal of Voice 1991; 5(1): 78-84.
12. Creighton FX, Hapner E, Klein A, Rosen A, Jin- nah HA, Johns MM.
Diagnostic delays in spasmodic dysphonia: a call for clinician education. Journal of Voice 2015; 29(5): 592-4.
13. Esposito M, Dubbioso R, Apisa p, Allocca R, Santoro L, Cesari u.
Spasmodic Dysphonia Fol- low-Up With Videolaryngoscopy and Voice Spec- trography During Treatment With Botulinum Toxin. Neurological Sciences 2015; 36(9): pp. 1679-82.
14. Dejonckere p, Neumann K, Moerman M, Martens J-P, Giordano A, Manfredi C. Tridimensional assessment of adductor spasmodic dysphonia pre- and post-treatment with Botulinum toxin.
European archives of oto-rhino- laryngology 2012; 269(4): 1195-203. 15. Kim JW, Park JH, Park KN, Lee sw. Treatment efficacy of electromyography versus fibersco- py-guided botulinum toxin injection in adductor spasmodic dysphonia patients: a prospective com- parative study. The Scientific World Journal 2014; 2014.
16. Mehta RP, Goldman SN, OrloffLA. Long-term therapy for spasmodic dysphonia: acoustic and aerodynamic outcomes. Archives of Otolaryngology- Head &Neck Surgery 2001; 127(4): 393-9.
17. Rosow DE, Parikh p, Vivero RJ, Casiano RR, Lundy DS. Considerations for initial dosing of bot- ulinum toxin in treatment of adductor spasmodic dysphonia. Otolaryngology-Head and Neck Surgery 2013; 148(6): 1003-6.
18. Bielamowicz s, Ludlow CL. Effects of botuli- num toxin on pathophysiology in spasmodic dys- phonia. Annals of Otology, Rhinology & Laryngology 2000; 109(2): 194-203.